Analysts at Zacks Investment Research upgraded shares of Selecta Biosciences Inc (NASDAQ: SELB) from Hold to Buy today. The company currently has a rating of Buy on the shares. The one-year price target of $22.50 is above the opening price …

Analysts at Zacks Investment Research upgraded shares of Selecta Biosciences Inc (NASDAQ: SELB) from Hold to Buy today.With a rating of Buy on the shares, Selecta Biosciences Inc has a 52-week high of $16.32. The one-year price target of $22.50 …